Name : Human HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer Protein
Product Source :
Recombinant Human MAGE-A3(HLA-A*01:01) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*01:01),Ile21-Met119(B2M) and EVDPIGHLY peptide.[Accession | Q5SUL5(HLA-A*01:01)&P61769(B2M)&EVDPIGHLY]
Molecular Weight :
The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer on Tris-Bis PAGE under Non reducing (N) condition. The purity is greater than 95%. SEC-HPLC The purity of Human HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer is greater than 95% as determined by SEC-HPLC.
Background :
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.
Synonyms :
Melanoma-associated antigen 3; MZ2-D; MZ2D; MZ2-D; CT1.3; MAGE-3
References & Citations :
Khalvandi A, Abolhasani M, Madjd Z, Shekarabi M, Kourosh-Arami M, Mohsenzadegan M. Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer. APMIS. 2021 Jun;129(6):291-303. doi: 10.1111/apm.13132. Epub 2021 Apr 13. PMID: 33743542.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
IL-18 Protein
IFN-beta Protein
Popular categories:
Carbonic Anhydrase 14 (CA-XIV)
c-Jun N-terminal kinase 2 (JNK2)